We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates
Read MoreHide Full Article
PRA Health Sciences, Inc. reported third-quarter 2019 adjusted earnings per share (EPS) of $1.32, which outpaced the Zacks Consensus Estimate of $1.30. The bottom line rose 16.8% from the prior-year quarter tally.
The Zacks Rank #2 (Buy) company registered revenues of $780.7 million in the quarter under review, up 8.8% year over year and 9.7% on a constant currency (cc) basis. Also, the figure surpassed the Zacks Consensus Estimate by 1.1%.
Q3 in Detail
Segmental Analysis
Net new business at the Clinical Research segment came in at $669.4 million in the third quarter. Through this segment, the company receives contracts from customers to provide clinical research services with payments based on fixed-fee or fee-for-service arrangements.
PRA Health Sciences, Inc. Price, Consensus and EPS Surprise
Revenues at the Clinical Research segment and Data Solutions segment amounted to $719 million and $61.7 million, respectively, in the quarter under review. The company provides weekly, monthly or quarterly data reports and analytics to customers.
Direct Costs
Direct costs totaled $389.3 million in the quarter, up 4.8% year over year. Per management, the increase in direct costs was primarily driven by an increase in labor-related costs in the Clinical Research segment.
Margin Trend
Operating profit in the quarter was $95.8 million, up significantly from the year-ago quarter’s figure of $38.8 million. Operating margin in the quarter was 12.3%, down significantly from the year-ago quarter’s 22.6%.
Financial Update
Cash and cash equivalents came in at $181.7 million, up 26% from the 2018-end level.
Guidance
For 2019, PRA Health expects revenues within $3.02-$3.10 billion, representing reported growth of 5-8% and 6-8% at cc. Notably, this is lower than the earlier provided range of $3.09-$3.20 billion, representing reported and cc growth of 8-11%, respectively. The Zacks Consensus Estimate of $3.06 billion is within the guided range.
Adjusted EPS is expected between $5.07 and $5.12, calling for year-over-year growth of 18-20%, higher than the earlier projected range of $4.98 and $5.08, mirroring year-over-year growth of 16-19%. The Zacks Consensus Estimate of $5.07 is at the low end of the guided range.
Our Take
PRA Health ended the third quarter on a mixed note. A raised EPS view and retained guidance for 2019 instills optimism. Strong performance by the Clinical Research segment is a positive. PRA Health continues to gain from large pharmaceutical companies, which contributed substantially to its top line in recent times. Management is optimistic about the integration of Symphony Health. With this buyout, PRA Health expects to enhance ability in the field of data and analytics. The company is also poised well on CRO market prospects.
On the flip side, direct costs shot up in the quarter under review. Contraction in operating margin is also worrisome.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the consensus estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.
ResMed reported fiscal first-quarter 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates
PRA Health Sciences, Inc. reported third-quarter 2019 adjusted earnings per share (EPS) of $1.32, which outpaced the Zacks Consensus Estimate of $1.30. The bottom line rose 16.8% from the prior-year quarter tally.
The Zacks Rank #2 (Buy) company registered revenues of $780.7 million in the quarter under review, up 8.8% year over year and 9.7% on a constant currency (cc) basis. Also, the figure surpassed the Zacks Consensus Estimate by 1.1%.
Q3 in Detail
Segmental Analysis
Net new business at the Clinical Research segment came in at $669.4 million in the third quarter. Through this segment, the company receives contracts from customers to provide clinical research services with payments based on fixed-fee or fee-for-service arrangements.
PRA Health Sciences, Inc. Price, Consensus and EPS Surprise
PRA Health Sciences, Inc. price-consensus-eps-surprise-chart | PRA Health Sciences, Inc. Quote
Revenues at the Clinical Research segment and Data Solutions segment amounted to $719 million and $61.7 million, respectively, in the quarter under review. The company provides weekly, monthly or quarterly data reports and analytics to customers.
Direct Costs
Direct costs totaled $389.3 million in the quarter, up 4.8% year over year. Per management, the increase in direct costs was primarily driven by an increase in labor-related costs in the Clinical Research segment.
Margin Trend
Operating profit in the quarter was $95.8 million, up significantly from the year-ago quarter’s figure of $38.8 million. Operating margin in the quarter was 12.3%, down significantly from the year-ago quarter’s 22.6%.
Financial Update
Cash and cash equivalents came in at $181.7 million, up 26% from the 2018-end level.
Guidance
For 2019, PRA Health expects revenues within $3.02-$3.10 billion, representing reported growth of 5-8% and 6-8% at cc. Notably, this is lower than the earlier provided range of $3.09-$3.20 billion, representing reported and cc growth of 8-11%, respectively. The Zacks Consensus Estimate of $3.06 billion is within the guided range.
Adjusted EPS is expected between $5.07 and $5.12, calling for year-over-year growth of 18-20%, higher than the earlier projected range of $4.98 and $5.08, mirroring year-over-year growth of 16-19%. The Zacks Consensus Estimate of $5.07 is at the low end of the guided range.
Our Take
PRA Health ended the third quarter on a mixed note. A raised EPS view and retained guidance for 2019 instills optimism. Strong performance by the Clinical Research segment is a positive. PRA Health continues to gain from large pharmaceutical companies, which contributed substantially to its top line in recent times. Management is optimistic about the integration of Symphony Health. With this buyout, PRA Health expects to enhance ability in the field of data and analytics. The company is also poised well on CRO market prospects.
On the flip side, direct costs shot up in the quarter under review. Contraction in operating margin is also worrisome.
Earnings of Other MedTech Majors at a Glance
Other top-ranked companies, which posted solid results this earnings season, are Edwards Lifesciences (EW - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and ResMed Inc. (RMD - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the consensus estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.
ResMed reported fiscal first-quarter 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>